Modified Rankin scale as a determinant of direct medical costs after stroke

Background Resource use in the acute and subacute phases after stroke depends on the degree of disability. Aims To determine if direct costs after stroke also vary by level of disability as measured using the modified Rankin scale at the chronic stage after stroke. Methods In a multicentre study, we collected acute and chronic in- and outpatient resource use in survivors of ischemic stroke stratified by levels of disability according to the modified Rankin Scale. Statistical inference on costs at each level of the modified Rankin Scale was estimated using a general linear model for the first three months, the first year, and any subsequent year after ischemic stroke. Results A total of 569 survivors of ischemic stroke with a mean age of 71.7 years were enrolled (41% female) from 10 academic and nonacademic centers. Costs varied substantially over time and with each modified Rankin Scale level. The total average costs in the first year were estimated $33,147 per patient, ranging from $9,114 for modified Rankin Scale 0 to $83,236 for modified Rankin Scale 5. In the second year, medical costs were on average $14,039, varying from $2,921 to $39,723 for patients with modified Rankin Scale 0–5. The level of disability based on the modified Rankin Scale was a major determinant of resource use, irrespective of age, gender, atrial fibrillation, and vascular risk factors. Conclusion Long-term resource use after stroke is high and is mainly driven by degree of disability as measured by the modified Rankin scale.

[1]  A. Thrift,et al.  Long-Term Costs of Stroke Using 10-Year Longitudinal Data From the North East Melbourne Stroke Incidence Study , 2014, Stroke.

[2]  Yilong Wang,et al.  Cost-Effectiveness of Thrombolysis within 4.5 Hours of Acute Ischemic Stroke in China , 2014, PloS one.

[3]  Michael D Hill,et al.  Impact of Disability Status on Ischemic Stroke Costs in Canada in the First Year , 2012, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[4]  Werner Hacke,et al.  Contemporary Outcome Measures in Acute Stroke Research: Choice of Primary Outcome Measure , 2012, Stroke.

[5]  L. Kalra,et al.  The Economic Burden of Stroke in the United Kingdom , 2012, PharmacoEconomics.

[6]  M. Koopmanschap,et al.  Lifetime health effects and medical costs of integrated stroke services - a non-randomized controlled cluster-trial based life table approach , 2010, Cost effectiveness and resource allocation : C/E.

[7]  B. Demaerschalk,et al.  US cost burden of ischemic stroke: a systematic literature review. , 2010, The American journal of managed care.

[8]  M. C. Christensen,et al.  Ischemic Stroke and Intracerebral Hemorrhage: The Latest Evidence on Mortality, Readmissions and Hospital Costs from Scotland , 2008, Neuroepidemiology.

[9]  H. Diener,et al.  Association Between Disability Measures and Healthcare Costs After Initial Treatment for Acute Stroke , 2007, Stroke.

[10]  J. Struijs,et al.  Future costs of stroke in the Netherlands: The impact of stroke services , 2006, International Journal of Technology Assessment in Health Care.

[11]  Bernhard Neundörfer,et al.  Lifetime Cost of Ischemic Stroke in Germany: Results and National Projections From a Population-Based Stroke Registry: The Erlangen Stroke Project , 2006, Stroke.

[12]  J. Caro,et al.  Care needs and economic consequences after acute ischemic stroke: the Erlangen Stroke Project , 2005, European journal of neurology.

[13]  W. Oertel,et al.  Resource utilization and costs of stroke unit care in Germany. , 2004, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[14]  P. Amarenco,et al.  Costs of Stroke Care according to Handicap Levels and Stroke Subtypes , 2003, Cerebrovascular Diseases.

[15]  S. Thompson,et al.  How should cost data in pragmatic randomised trials be analysed? , 2000, BMJ : British Medical Journal.